OrbitonOpen research workspace →

EyePoint Pharmaceuticals Inc.

NASDAQ:EYPTLive AI agent

EyePoint is committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases.

Investor website: https://eyepoint.bio/

About

EyePoint is committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. Their retinal disease-focused pipeline leverages proprietary Durasert E™ technology, enabling the potential to preserve vision with less burden. Durasert® has been safely administered to thousands of patients’ eyes across four FDA approved products.

Verified company data

Projects
["Durasert E™\n- Bioerodible version of the proven, safe Durasert® technology\n- Delivered via standard in-office IVT injection\n- No delay – reaches target tissue at therapeutic levels within hours\n- No free-floating drug – drug is delivered for at least six months before the remaining matrix fully bio-erodes\n\nEyePoint history of Durasert E™ technology – proven safety in thousands of eyes across 4 FDA- approved products, Vitrasert® (B&L), Retisert® (B&L), ILUVIEN® (ANI Pharmaceuticals) and YUTIQ® (ANI Pharmaceuticals)"]
Leadership
Jay S. Duker, M.D. (President & CEO and Board Director, Jay S. Duker, M.D. is the President & CEO and Board Director of EyePoint, a biopharmaceutical company that develops sustained-release medications to treat serious ocular disorders. Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings.), George O. Elston (Executive Vice President, Chief Financial Officer, As Executive Vice President, Chief Financial Officer, George O. Elston leads EyePoint’s financial, capital markets, and corporate development initiatives. Mr. Elston has leveraged his more than 30 years of diverse financial and senior leadership in the biopharmaceutical sector to propel the Company’s strategic, operational, and business goals forward.), Ramiro Ribeiro, M.D., Ph.D. (Chief Medical Officer, Ramiro Ribeiro, M.D., Ph.D. is a retinal specialist and the Chief Medical Officer of EyePoint. He leads the Clinical Development, Clinical Operations and Medical Safety teams at EyePoint with a profound commitment in innovation to advance patient care and medical excellence.), Tarek S. Hassan, M.D. (Chief Strategic Science Officer, As Chief Strategic Science Officer, Tarek S. Hassan, M.D., leverages over 35 years of experience as a globally recognized retina specialist and key opinion leader to provide strategic guidance across the Company’s portfolio to optimize development, potential commercialization, and growth opportunities for EyePoint’s pipeline.), Michael Campbell (Chief Commercial Officer, As Chief Commercial Officer, Michael Campbell leads EyePoint’s commercial strategy and operations, leveraging over 30 years of commercial leadership experience, where he scaled global commercial organizations and pioneered patient-focused strategies for commercializing innovative ophthalmologic products.), Ron Honig Esq. (Chief Legal Officer & Company Secretary, As Chief Legal Officer & Company Secretary, Ron Honig leads in-house counsel for EyePoint, using his more than 30 years of experience in corporate governance, securities law compliance, and mergers and acquisitions to support the Company’s business priorities.), Isabelle Lefebvre (Chief Regulatory Officer, As Chief Regulatory Officer, Isabelle Lefebvre is responsible for EyePoint’s regulatory strategy and compliance, with a focus on bringing innovative products to patients in the US and around the world.), Jennifer Leonard (Chief People Officer and SVP, IT, As Chief People Officer & Senior Vice President, Information Technology, Jennifer Leonard uses her more than 30 years of strategic human resources management and information technology (IT) expertise to drive EyePoint’s talent and IT growth activities.), Michael J. Maciocio (Chief Manufacturing Officer, As Chief Manufacturing Officer, Michael Maciocio leads EyePoint’s manufacturing and supply chain strategy, with a focus on ensuring clinical and commercial supply of innovative products is brought to patients within the US and globally.), Marcia Sellos-Moura, Ph.D. (Chief Scientific Officer, Marcia Sellos-Moura, Ph.D., has broad biopharmaceutical experience in program and portfolio strategy and management, operations planning and execution, and in business development. For over 20 years, Dr. Sellos-Moura has worked across all phases of drug development and in multiple therapeutic areas.)

Verified data last updated:

Recent filings